{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-279803","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2026-06-23T21:28:13+00:00","discovered_at":"2026-06-23T21:30:00.251897+00:00","generated_at":"2026-06-23T21:30:24.733077+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Enanta loses Federal Circuit appeal; Paxlovid patent claims invalidated","bullets":["Federal Circuit affirmed Dec 2024 summary judgment, ruling claims of U.S. Patent No. 11,358,953 invalid.","Patent covered Pfizer's COVID-19 antiviral Paxlovid (nirmatrelvir; ritonavir).","Enanta had sought damages for infringement; appeal loss eliminates potential royalty stream.","Decision issued on June 23, 2026 by the U.S. Court of Appeals for the Federal Circuit."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-279803","json":"https://secwatch.observer/filing/0001193125-26-279803.json","markdown":"https://secwatch.observer/filing/0001193125-26-279803.md","text":"https://secwatch.observer/filing/0001193125-26-279803.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526279803/0001193125-26-279803-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526279803/d133783d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T21:30:24.733077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}